These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

682 related items for PubMed ID: 15194567

  • 21. Psoriatic arthritis patients doing better on infliximab than etanercept.
    Smith N, Gadsby K, Deighton C.
    Rheumatology (Oxford); 2007 Apr; 46(4):721-2. PubMed ID: 17314216
    [No Abstract] [Full Text] [Related]

  • 22. Psoriatic onychopachydermoperiostitis: improvement with etanercept.
    Dans M, Hivnor C, van Voorhees AS.
    Br J Dermatol; 2005 Oct; 153(4):858-9. PubMed ID: 16181482
    [No Abstract] [Full Text] [Related]

  • 23. Severe refractory rheumatoid arthritis successfully treated with combination rituximab and anti-tumor necrosis factor-alpha-blocking agents.
    Koumakis E, Wipff J, Avouac J, Kahan A, Allanore Y.
    J Rheumatol; 2009 Sep; 36(9):2125-6. PubMed ID: 19738227
    [No Abstract] [Full Text] [Related]

  • 24. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L, Mouthon L.
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The role of tumor necrosis factor inhibitors in patients with RA.
    Trethewey P.
    JAAPA; 2002 Sep; 15(9):23-4, 27, 30 passim. PubMed ID: 12395668
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis.
    Goedkoop AY, Kraan MC, Teunissen MB, Picavet DI, de Rie MA, Bos JD, Tak PP.
    Ann Rheum Dis; 2004 Jul; 63(7):769-73. PubMed ID: 15194570
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Superimposed linear psoriasis: low effectiveness of biologic therapy.
    Colombo L, Marconi M, Mapelli ET, Crespi E, Gualandri L, Menni S, Cerri A.
    G Ital Dermatol Venereol; 2011 Aug; 146(4):311-3. PubMed ID: 21785401
    [No Abstract] [Full Text] [Related]

  • 33. Tumor necrosis factor blockers in rheumatoid arthritis.
    Pisetsky DS.
    N Engl J Med; 2000 Mar 16; 342(11):810-1. PubMed ID: 10717018
    [No Abstract] [Full Text] [Related]

  • 34. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach.
    Gordon KB, Ruderman EM.
    J Am Acad Dermatol; 2006 Mar 16; 54(3 Suppl 2):S85-91. PubMed ID: 16488334
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Developing a new generation of TNFalpha antagonists for the treatment of rheumatoid arthritis.
    Fleischmann R, Shealy D.
    Mol Interv; 2003 Sep 16; 3(6):310-8. PubMed ID: 14993463
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Malignancies developing in obese patients with psoriasis while on antitumour necrosis factor-α therapies: a case series.
    Sadlier M, Lally A, Kirby B.
    Br J Dermatol; 2012 Oct 16; 167(4):937-8. PubMed ID: 22428935
    [No Abstract] [Full Text] [Related]

  • 39. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis?
    Kaplan MJ.
    Nat Clin Pract Rheumatol; 2005 Dec 16; 1(2):74-5. PubMed ID: 16932633
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 35.